These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 26497099)

  • 1. PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
    Warnke C; Olsson T; Hartung HP
    Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
    Peaureaux D; Pignolet B; Biotti D; Bucciarelli F; Gaina J; Bucur C; Clanet M; Martin-Blondel G; Brassat D
    Mult Scler; 2015 Apr; 21(5):671-2. PubMed ID: 25305251
    [No Abstract]   [Full Text] [Related]  

  • 3. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
    Reuwer AQ; Heron M; van der Dussen D; Schneider-Hohendorf T; Murk JL
    Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [[Natalizumab therapy, 2013].
    Karácsony M; Bencsik K; Vécsei L
    Ideggyogy Sz; 2014 Jul; 67(7-8):220-8. PubMed ID: 25509362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.
    Anton R; Haas M; Arlett P; Weise M; Balabanov P; Mazzaglia G; Prieto L; Keller-Stanislawski B; Raine J
    Clin Pharmacol Ther; 2017 Aug; 102(2):283-289. PubMed ID: 28001298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis.
    Dubey D; Cano CA; Stüve O
    Curr Opin Neurol; 2016 Jun; 29(3):278-85. PubMed ID: 27027553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New aspects of immunotherapy in multiple sclerosis].
    Pape K; Zipp F; Bittner S
    Nervenarzt; 2018 Dec; 89(12):1365-1370. PubMed ID: 29881971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.
    Calic Z; Cappelen-Smith C; Hodgkinson SJ; McDougall A; Cuganesan R; Brew BJ
    J Clin Neurosci; 2015 Mar; 22(3):598-600. PubMed ID: 25523125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Oshima Y; Tanimoto T; Yuji K; Tojo A
    Mult Scler; 2019 Jul; 25(8):1141-1149. PubMed ID: 29985084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification.
    Pitarokoili K; Gold R
    Nat Rev Neurol; 2017 Dec; 13(12):710-712. PubMed ID: 29146954
    [No Abstract]   [Full Text] [Related]  

  • 12. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL; Tyor WR
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of disease-modifying therapies after switching from natalizumab.
    Zeineddine M; Al-Roughani R; Farouk Ahmed S; Khoury S; El-Ayoubi N; Al-Mahdawi A; Al-Khabouri J; Al-Asmi A; Chentouf A; Inshasi J; Gouider R; Mrabet S; Shalaby N; Massouh J; Mohamed Ramzy Hasan Mohamed F; Al-Hajje A; Salameh P; Dimassi H; Boumediene F; Yamout B
    Mult Scler; 2024 Jul; 30(8):1026-1035. PubMed ID: 39054846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple sclerosis, natalizumab, and PML: helping patients decide.
    Rudick RA
    Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S18-23. PubMed ID: 22123928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
    Bacchetta F; Mathias A; Schluep M; Du Pasquier R
    Mult Scler; 2017 Feb; 23(2):300-303. PubMed ID: 28165319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.
    D'Amico E; Zanghì A; Leone C; Tumani H; Patti F
    Drug Saf; 2016 Dec; 39(12):1163-1174. PubMed ID: 27696299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.
    Schwab N; Schneider-Hohendorf T; Wiendl H
    Int Immunol; 2015 Jan; 27(1):47-53. PubMed ID: 25326459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
    Giovannoni G; Marta M; Davis A; Turner B; Gnanapavan S; Schmierer K
    Pract Neurol; 2016 Oct; 16(5):389-93. PubMed ID: 27114560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
    Cutter GR; Stüve O
    Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned.
    Major EO; Yousry TA; Clifford DB
    Lancet Neurol; 2018 May; 17(5):467-480. PubMed ID: 29656742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.